- Home
- HBCP vs KROS Comparison
HBCP vs KROS Comparison
Compare HBCP & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HBCP | KROS |
|---|---|---|
| Founded | 1908 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 495.8M | 584.9M |
| IPO Year | 2008 | 2020 |
Fundamental Metrics
Financial Performance| Metric | HBCP | KROS |
|---|---|---|
| Price | $63.04 | $17.57 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $63.50 | $23.00 |
| AVG Volume (30 Days) | 37.8K | ★ 299.9K |
| Earning Date | 01-26-2026 | 02-25-2026 |
| Dividend Yield | ★ 1.97% | N/A |
| EPS Growth | ★ 29.01 | N/A |
| EPS | ★ 5.87 | 1.57 |
| Revenue | $148,656,000.00 | ★ $246,718,000.00 |
| Revenue This Year | N/A | $6,924.79 |
| Revenue Next Year | $9.09 | N/A |
| P/E Ratio | ★ $10.74 | $11.16 |
| Revenue Growth | 12.31 | ★ 37798.31 |
| 52 Week Low | $39.59 | $9.12 |
| 52 Week High | $64.17 | $22.55 |
Technical Indicators
Market Signals| Indicator | HBCP | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 59.32 | 37.93 |
| Support Level | $61.56 | $17.22 |
| Resistance Level | $63.37 | $18.74 |
| Average True Range (ATR) | 1.93 | 0.66 |
| MACD | 0.12 | -0.12 |
| Stochastic Oscillator | 71.06 | 4.78 |
Price Performance
Historical ComparisonAbout HBCP Home Bancorp Inc.
Home Bancorp Inc is engaged in attracting deposits from the public and using those funds to invest in loans and securities. The principal sources of funds are customer deposits, repayments of loans, repayments of investments and funds borrowed from outside sources such as the Federal Home Loan Bank of Dallas. These funds are used for the origination of loans, including one-to-four-family first mortgage loans, home equity loans, and lines, commercial real estate loans, construction and land loans, multi-family residential loans, commercial and industrial loans, and consumer loans.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.